Overview

A Study to Assess the Bioavailability of Risankizumab Following Subcutaneous Administration With Prefilled Pen Relative to a Prefilled Syringe in Healthy Adult Participants

Status:
ACTIVE_NOT_RECRUITING

Trial end date:
2026-01-01

Target enrollment:

Participant gender:

Summary

This study will assess the pharmacokinetics, relative bioavailability, immunogenicity, safety, and tolerability of risankizumab following subcutaneous (SC) administration with a prefilled pen or a prefilled syringe in healthy adult participants.

Phase:

PHASE1

Details

Lead Sponsor:

AbbVie

Treatments:

risankizumab